Jiri Pavlu is a Consultant Haematologist at Hammersmith Hospital and Honorary Clinical Senior Lecturer at Imperial College London. He graduated from the First Faculty of Medicine of Charles University in Prague in 1998. In completing this he was part of the research group of Professor Gordon-Smith at St.Georges Hospital Medical School in London and obtained his research degree in molecular haematology. He completed his specialist haematology training in London on the Royal Free and Hammersmith rotation.
He has developed a specialist interest in haematopoietic stem cell transplantation, particularly for leukaemia. He is the clinical lead for acute leukaemia and myelodysplastic syndromes and a stem cell transplant clinical and collection facility director. Together with Gill Brisley, clinical nurse specialist, and the transplant coordinators he runs relevant specialist haematology clinics at Hammersmith Hospital. He is a principal investigator and subinvestigator of various clinical trials, an active member of the European Group for Blood and Marrow Transplantation (EBMT) Acute leukaemia working party and also an accredited inspector for the Joint Accreditation Committee – International Society for Cellular Therapy (Europe) & EBMT.
Secretary: +44 (0) 2083838117, +44 (0) 2083835030
Fax: +44 (0) 2033133965
et al., 2020, The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants., Nat Commun, Vol:11
et al., 2020, Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative, Bone Marrow Transplantation, ISSN:0268-3369
et al., 2019, A multi-species cluster of GES-5 carbapenemase producing Enterobacterales linked by a geographically disseminated plasmid, Clinical Infectious Diseases, ISSN:1058-4838
et al., 2019, Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT, Journal of Hematology and Oncology, Vol:12, ISSN:1756-8722, Pages:1-9
et al., 2019, Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality., Leukemia, Vol:34, ISSN:1476-5551, Pages:667-670